Thermo Fisher Scientific ($TMO) podcast mentions
Welcome back. I'm here at Morgan Stanley's 2026 Global Healthcare Conference that brings together some big names, of course, in pharma and biotech, as you might expect. Joining us now to see joining us now for an exclusive is Thermo Fisher Scientific's Chairman and CEO, Mark Casper. Nice to have you here.
David Faber · Squawk on the Street · 10AM Hour: Treasury Sec. Bessent Testifies, Thermo Fisher CEO, Morgan Stanley’s M&A Outlook 9/15/26 · 2026-09-15Yeah. So one of the things in the pharmaceutical and biotech industry is what ultimately drives it is bringing successful medicines to market. And the higher the returns on those investments, the more virtuous the cycle is. So when you hear about new modalities or new therapeutic areas that are having success, that ultimately spurs more investment. And AI is helping to kill ineffective medicines faster so that you don't spend money on things that don't work. And at the same point in time, shortening the time to market for those things that do work. And that gives you a longer return cycle on an approved medicine. And that also will spur more investment. So we're very excited about what the technology is doing and ultimately how we're applying it at Thermo Fisher Scientific.
Marc Casper · Squawk on the Street · 10AM Hour: Treasury Sec. Bessent Testifies, Thermo Fisher CEO, Morgan Stanley’s M&A Outlook 9/15/26 · 2026-09-15